Discounted Cash Flow (DCF) Analysis Levered
KORU Medical Systems, Inc. (KRMD)
$3.9
-0.02 (-0.51%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 15.44 | 17.35 | 23.16 | 24.18 | 23.49 | 26.27 | 29.39 | 32.87 | 36.76 | 41.12 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -0.33 | 1.48 | 0.32 | -0.74 | -4.32 | -0.72 | -0.81 | -0.90 | -1.01 | -1.13 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.42 | -0.48 | -0.43 | -1.06 | -0.35 | -0.69 | -0.77 | -0.87 | -0.97 | -1.08 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -0.75 | 1 | -0.10 | -1.80 | -4.67 | -1.41 | -1.58 | -1.77 | -1.97 | -2.21 |
Weighted Average Cost Of Capital
| Share price | $ 3.9 |
|---|---|
| Beta | 0.328 |
| Diluted Shares Outstanding | 44.39 |
| Cost of Debt | |
| Tax Rate | -65.25 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 5.081 |
| Total Debt | 0.10 |
| Total Equity | 173.10 |
| Total Capital | 173.20 |
| Debt Weighting | 0.06 |
| Equity Weighting | 99.94 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 15.44 | 17.35 | 23.16 | 24.18 | 23.49 | 26.27 | 29.39 | 32.87 | 36.76 | 41.12 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -0.33 | 1.48 | 0.32 | -0.74 | -4.32 | -0.72 | -0.81 | -0.90 | -1.01 | -1.13 |
| Capital Expenditure | -0.42 | -0.48 | -0.43 | -1.06 | -0.35 | -0.69 | -0.77 | -0.87 | -0.97 | -1.08 |
| Free Cash Flow | -0.75 | 1 | -0.10 | -1.80 | -4.67 | -1.41 | -1.58 | -1.77 | -1.97 | -2.21 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -2.25 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -25.24 |
| Equity Value | - |
| Shares Outstanding | 44.39 |
| Equity Value Per Share | - |